Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;4(3):204-9.
doi: 10.1111/j.1752-8062.2011.00280.x.

Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy

David M Haas  1 , Beverly Gallauresi, Kristine Shields, Deborah Zeitlin, Shannon M Clark, Mary F Hebert, Zhaoxia Ren, Srikanth C Nallani, Eric M Meslin, Karen B Feibus, Gideon Koren, W Scott Goebel, Thomas Easterling, Scott C Denne, David A Flockhart, Jamie L Renbarger
Affiliations

Pharmacotherapy and pregnancy: highlights from the Third International Conference for Individualized Pharmacotherapy in Pregnancy

David M Haas et al. Clin Transl Sci. 2011 Jun.

Abstract

To address provider struggles to provide evidence-based, rational drug therapy to pregnant women, this third Conference was convened to highlight the current progress and research in the field. Speakers from academic centers, industry, and governmental institutions spoke about: the Food and Drug Administration's role in pregnancy pharmacology and the new labeling initiative; drug registries in pregnancy; the pharmacist's role in medication use in pregnancy; therapeutic areas such as preterm labor, gestational diabetes, nausea and vomiting in pregnancy, and hypertension; breast-feeding and medications; ethical challenges for consent in pregnancy drug studies; the potential for cord blood banks; and concerns about the fetus when studying drugs in pregnancy. The Conference highlighted several areas of collaboration within the current Obstetrics Pharmacology Research Units Network and hoped to educate providers, researchers, and agencies with the common goal to improve the ability to safely and effectively use individualized pharmacotherapy in pregnancy.

PubMed Disclaimer

References

    1. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K, McPhillips H, Raebel MA, Roblin D, Smith DH, et. al. Prescription drug use in pregnancy. Am J Obstet Gynecol. 2004; 191(2): 398–407. - PubMed
    1. Engeland A, Bramness JG, Daltveit AK, Ronning M, Skurtveit S, Furu K. Prescription drug use among fathers and mothers before and during pregnancy. A population‐based cohort study of 106,000 pregnancies in Norway 2004‐2006. Br J Clin Pharmacol. 2008; 65(5): 653–660. - PMC - PubMed
    1. Updated Interim Recommendations for Obstetric Health Care Providers Related to Use of Antiviral Medications in the Treatment and Prevention of Influenza for the 2009‐2010 Season. The Centers for Disease Control and Prevention. 2009. [cited 2009 September 24]; Available from: http://www.cdc.gov/H1N1flu/pregnancy/antiviral_messages.htm.
    1. United States General Accounting Office GAO/HRD‐93‐17. Women’s Health – FDA needs to ensure more study of gender differences in prescription drug testing. 1992.
    1. Hebert MF, Carr DB, Anderson GD, Blough D, Green GE, Brateng DA, Kantor E, Benedetti TJ, Easterling TR. Pharmacokinetics and pharmacodynamics of atenolol during pregnancy and postpartum. J Clin Pharmacol. 2005; 45(1): 25–33. - PubMed

Publication types